Agree, hate it when companies 'dilute' even tho I u/stand the evil necessity of doing so.
And with their 'other' developments so far away from even reaching the PH 3 stage, all they have going is this first product. And I have no idea what their revenue stream 'could be'. I recall someone saying a market cap of $600 Million or so, but I don't recall seeing the 'justification' for it. That would be around a $24/sh share price, thanks to the new shares (I had $30 for a target price at 14 Million shares)...
So, because of these additional shares, messy market, I decided to sell the Nov $7.5s the other day for around a $/. Decided its time to start getting 'something' cause once the data is released, its a 9 month+ long slog to the decision day. And then the bio sector ETFs lit up (IBB, XBI to name the big ones) and I suspect helped pop the share price. So at present, my shares are up for grabs in Nov for $7.5 (go figure)..
Ok, they said data by the end of the year. See when it comes out, was 'hoping' for Dec. And then planned to sell covered calls for the next few months while we waited. But to close, yeah, the doubling plus some of the share count post the r/split (11 Mil to now 25 Mil) has taken away more of the 'expectations' in terms of share price than I like to see.
Now to see if this pulls back some, see if the bio sector stays hot or if this is a short term 'blip'... Cause nothing has changed in terms of the economic outlook for the US other than, its likely to get worse for a while..
